VIRBAC Stock: Up 2.4% at Close, Shares Break Through Resistance After Strong Quarterly Results
The veterinary laboratory based in Nice continues its rebound this Monday, October 20, closing at 341.50 euros, extending the sharp rise that began last Friday. The stock thus records a weekly performance of over 10% following the publication of its third-quarter 2025 results, marked by a clear acceleration in growth and an upward revision of annual targets. This upward trend has allowed the price to break through its main technical resistance threshold.
Current Trading Performance
Virbac's stock showed a rise of 2.4% to 341.50 euros this Monday, after closing at 333.50 euros last Friday. This new advance brings the stock's weekly performance to 10.16%, a dynamic that contrasts with the trajectories of recent months: the stock remains down by 3.67% over three months and by 1.16% over a year. For comparison, the CAC 40 gained 0.39% this Monday and shows an increase of 7.79% over twelve months. The capital turnover stands at only 0.07% of the market capitalization, indicating limited trading volumes despite the bullish movement. The stock is now trading significantly above its reference moving averages, located at 323.36 euros for the 50-day average and 318.50 euros for the 200-day average. This configuration illustrates the recovery initiated by the price after several weeks of hesitation.
Impact of Q3 Results on Stock Performance
The rebound in the stock occurred following the publication on Friday, October 17, of the third-quarter results, which marked a sharp acceleration in business dynamics. The group recorded a growth of 12.5% in comparable data for the period, after 6.4% in the second quarter and 4.9% in the first. This performance was particularly driven by North America, where sales jumped 48.5% in comparable data, supported by restocking operations at a major distributor. Over the first nine months of the year, revenues grew by 7.8% at constant exchange rates and scope to reach 1.102 billion euros. With these results, the laboratory has raised its annual growth forecast, now expected between 5.5% and 7% in comparable data versus a previously expected range of 4% to 6%. The current operating margin remains targeted at 16%, while the cash position is expected to improve by about 80 million euros over the fiscal year. This publication was described as robust by analysts, contributing to the strong rise of 7.23% recorded last Friday.
Technical Analysis of the Stock
From a technical standpoint, the price has broken through its resistance threshold located at 333.50 euros, while the support remains at 307.50 euros. The RSI indicator is at 64 points, suggesting positive momentum without an overbought configuration. The stock is also trading above the upper Bollinger band established at 326.96 euros, signaling a strong bullish dynamic. The MACD histogram also shows a positive value at 1.24, with the MACD line at -1.30 and the signal line at -2.54. The one-month volatility is recorded at 8.87, a moderate level reflecting the amplitude of recent variations in the stock. The beta coefficient, particularly low at 0.05, indicates that the stock has a very low correlation with overall market movements, evolving according to dynamics specific to it. The Chaikin Money Flow, an indicator of buying or selling pressure, is slightly positive at 0.02.
